U.S. FDA enforcement against compounded GLP-1 products highlights false equivalence claims on safety and efficacy, and Brazil faces a similar clinic-driven market—calling for ANVISA to tighten oversight, curb trademark misuse, and enforce compounding and dispensing rules.

Brazil can unlock leadership in clinical trials by pairing its new legal framework with clear implementing rules, better transparency tools, and technology integration—especially AI-enabled Real-World Evidence—while balancing IP protection and patient access.

Mega-events depend on strong IP frameworks—spanning trademarks, copyright, designs, and patents—to preserve exclusivity, curb counterfeiting and ambush marketing, and protect investments from organizers and sponsors while enabling technology used during the events.

Brazil’s new gaming law (Law 14,852/2024) broadens IP protection for electronic games—linking software and devices, opening a BRPTO registration path, and foreshadowing tighter, more specialized enforcement—while court practice and international models shape the next phase for disputes.

BRPTO has extended to October 27 the public comment deadline on proposed Chemistry-chapter guidelines for new uses of known products, which tighten novelty/obviousness and enablement standards—requiring in vivo data at filing and limiting support to exactly tested compounds.

Brazil’s luxury market is expanding despite global softness, and a stronger IP toolkit—position marks, trade dress, copyright, border measures, and favorable court rulings—is shaping a robust anti-counterfeiting environment.

Cybersecurity’s rise as a national-security imperative revives debate on compulsory licensing, but because effective defense depends on trade secrets and operational know-how, any emergency use must be narrowly tailored to avoid exposing sensitive methods while preserving incentives for R&D and cooperation with rightsholders.

ANVISA’s new 2025–2026 Operational Tactical Plan aims to reduce marketing approval backlogs by allowing applicants to replace pending submissions before formal review and by granting priority review for GLP‑1 receptor agonists.

The scientific significance of microbial consortia, their applications in biotechnology, and the challenges of obtaining patent protection in Brazil under BRPTO regulations.

A new chapter in Brazil’s IP scene has begun with the launch of RNA Law, an elite boutique firm dedicated to IP litigation, prosecution, and transactions.

BRPTO introduces a new appeal stage workflow to improve patent examination, focusing on enhancing consistency and efficiency in Brazil’s patent appeal process

Brazilian Congress to debate whether AI can be recognized as an inventor in patents

Explores the impact of Brazil’s updated rules on administrative appeals and their implications for patent stakeholders.

Comparative analysis of sequence listing requirements in divisional patent applications between EPO and BRPTO.

Projeto de Lei apresentado na Câmara propõe alteração na Lei da Propriedade Industrial

Governo lança programa "Mover" para promover sustentabilidade em automóveis, investimentos em P&D e atrair plantas industriais estrangeiras.

Antes da ampla adoção de computadores quânticos, há necessidade de padronização e desenvolvimento de técnicas de criptografia mais complexas para eliminar riscos à privacidade

Legal implications and challenges of quantum computing and AI in Brazil

Risks associated with evolving biosimilar regulations and pharmacovigilance in Brazil

Examination of how COVID-19 has affected IP law and practice in Brazil

Brazil prepares to introduce regulations for cannabis-based pharmaceuticals

The Brazilian Supreme Court case that could reshape the country’s patent system

Brazil’s Supreme Court sets earlier date for deciding 10-year patent term fate

Bolsonaro vetoes Brazil’s pioneering compulsory tech transfer law, sparking debate